DE60324544D1 - Muskarin antagonisten - Google Patents

Muskarin antagonisten

Info

Publication number
DE60324544D1
DE60324544D1 DE60324544T DE60324544T DE60324544D1 DE 60324544 D1 DE60324544 D1 DE 60324544D1 DE 60324544 T DE60324544 T DE 60324544T DE 60324544 T DE60324544 T DE 60324544T DE 60324544 D1 DE60324544 D1 DE 60324544D1
Authority
DE
Germany
Prior art keywords
sup
formula
compound
muscarin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324544T
Other languages
English (en)
Inventor
Craig D Boyle
William J Greenlee
Samuel Chackalamannil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE60324544D1 publication Critical patent/DE60324544D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60324544T 2002-04-26 2003-04-24 Muskarin antagonisten Expired - Lifetime DE60324544D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
PCT/US2003/012694 WO2003091220A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Publications (1)

Publication Number Publication Date
DE60324544D1 true DE60324544D1 (de) 2008-12-18

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324544T Expired - Lifetime DE60324544D1 (de) 2002-04-26 2003-04-24 Muskarin antagonisten

Country Status (12)

Country Link
US (1) US6890936B2 (de)
EP (1) EP1499596B1 (de)
JP (2) JP4527408B2 (de)
CN (1) CN1649845A (de)
AT (1) ATE413388T1 (de)
AU (1) AU2003228674A1 (de)
CA (1) CA2484217A1 (de)
DE (1) DE60324544D1 (de)
ES (1) ES2315494T3 (de)
HK (1) HK1068136A1 (de)
MX (1) MXPA04010552A (de)
WO (1) WO2003091220A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617419A1 (de) 2003-04-24 2013-07-24 Incyte Corporation Azaspiroalkanderivate als Hemmer von Metallproteasen
WO2006034089A1 (en) * 2004-09-20 2006-03-30 Targacept, Inc. Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity
CA2620333A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2066355A2 (de) * 2006-09-19 2009-06-10 Braincells, Inc. Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese
CA2664421A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Hmg coa reductase mediated modulation of neurogenesis
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
EP2089383B1 (de) 2006-11-09 2015-09-16 Probiodrug AG 3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
EA200901140A1 (ru) 2007-03-01 2010-04-30 Пробиодруг Аг Новое применение ингибиторов глутаминилциклазы
ES2533484T3 (es) 2007-04-18 2015-04-10 Probiodrug Ag Derivados de tiourea como inhibidores de la glutaminil ciclasa
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US20110281853A1 (en) 2010-05-12 2011-11-17 Rishi Arora Compositions and methods for treating or preventing atrial fibrillation
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EP3212637B1 (de) 2014-10-31 2021-06-02 Indivior UK Limited Dopamin d3 rezeptor antagonisten
JP6899043B2 (ja) 2015-05-22 2021-07-07 エージンバイオ, インコーポレイテッド レベチラセタムの持続放出性医薬組成物
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1999032489A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Also Published As

Publication number Publication date
US20040067972A1 (en) 2004-04-08
EP1499596A1 (de) 2005-01-26
WO2003091220A1 (en) 2003-11-06
ES2315494T3 (es) 2009-04-01
JP4527408B2 (ja) 2010-08-18
HK1068136A1 (en) 2005-04-22
AU2003228674A1 (en) 2003-11-10
CA2484217A1 (en) 2003-11-06
EP1499596B1 (de) 2008-11-05
JP2006507220A (ja) 2006-03-02
ATE413388T1 (de) 2008-11-15
MXPA04010552A (es) 2005-01-25
CN1649845A (zh) 2005-08-03
US6890936B2 (en) 2005-05-10
JP2010059213A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
DE60324544D1 (de) Muskarin antagonisten
ATE425149T1 (de) ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN
IS6658A (is) Ný efnasambönd
BRPI0410630A (pt) antagonista de nk1
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
ATE253063T1 (de) 5-ht1f-agonisten
SE0101675D0 (sv) Novel composition
ATE433447T1 (de) Pyrimiidinverbindungen
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PT1263724E (pt) Novos compostos
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
ATE410203T1 (de) Lipase-hemmende zusammensetzung
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
BR0212899A (pt) Compostos orgânicos
BG105710A (en) 5ht1 antagonists for antidepressant therapy
SE0303280D0 (sv) Novel compounds
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
NO20002408D0 (no) 5-HT1F antagonister
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
GB0223223D0 (en) Organic compounds
ATE384713T1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine und -piperidine als faktor-xa-antagonisten
NO20042729L (no) Heksasykliske forbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition